Floatz logo

Vincristine sulfate

Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2/3Active
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
95/ 100

Competitive context

252 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
MELPHALAN
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Adriamycin
Beth Israel Deaconess Medical Center
Phase 4BBB
Prednisone
Beth Israel Deaconess Medical Center
Phase 4BBB
Nivestim
Ruijin Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Vincristine sulfate is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative · Phase 3
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
Burkitt lymphomaActive
BBB
Indicative · Phase 2
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →